Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Blood (2023) 142 (20): 1697–1707.

https://doi.org/10.1182/blood.2023020630

Published: 2023

Includes: Supplemental data

Journal Articles

Changing treatment changing prognosis of mutations

Paresh Vyas

Blood (2023) 142 (19): 1583–1585.

https://doi.org/10.1182/blood.2023021769

Published: 2023

Journal Articles

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Blood (2023) 142 (Supplement 1): 730.

https://doi.org/10.1182/blood-2023-181593

Published: 2023

Journal Articles

Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A -Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers

I-Jun Lau, Joe R Harman, Nicole E Jackson, Nicholas Denny, Alastair L Smith, Paresh Vyas, James Oliver Davies, Jim Hughes, Nicholas Crump, Thomas Arthur Milne

Blood (2023) 142 (Supplement 1): 40.

https://doi.org/10.1182/blood-2023-185172

Published: 2023

Journal Articles

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2023-173413

Published: 2023

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

GATA1 Target Gene CSF2RB Is Functionally Coupled to MPL and Marks a TPO-Dependent Preleukemic TAM Cell Population Sustained By the Fetal Liver but Not Bone Marrow

David Cruz Hernandez, Nicolas Papadopoulos, Elise Sepulchre, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Leila Varghese, Gabriel Levy, Irene Roberts, Stefan N Constantinescu, Paresh Vyas

Blood (2023) 142 (Supplement 1): 404.

https://doi.org/10.1182/blood-2023-174449

Published: 2023

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Lisa Johnson, Yajia Zhang, Biao Li, Lisa Aviles, Indu Lal, Giri Ramsingh, Naval Daver, Paresh Vyas, David A. Sallman

Blood (2022) 140 (Supplement 1): 6934–6935.

https://doi.org/10.1182/blood-2022-160337

Published: 2022

Journal Articles

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2 -Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Prodromos Chatzikyriakou, Douglas RA Silveira, Maria del Pilar Casares Aláez, Batchimeg Usukhbayar, Marlen Metzner, Paresh Vyas, Anita K. Gandhi, Alberto Risueño, Maroof Hasan, Lynn Quek

Blood (2022) 140 (Supplement 1): 3414–3415.

https://doi.org/10.1182/blood-2022-163717

Published: 2022

Journal Articles

Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia

Sven Turkalj, Niels Asger Jakobsen, Angus Groom, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Kevin Clark, E. Ravza Gür, Lance D. Hentges, Paul Sopp, James O.J. Davies, Jim R. Hughes, Paresh Vyas

Blood (2022) 140 (Supplement 1): 1193–1194.

https://doi.org/10.1182/blood-2022-163139

Published: 2022

Journal Articles

Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation

Niels Asger Jakobsen, Sven Turkalj, Bilyana Stoilova, Marlen Metzner, Rachel Moore, Batchimeg Usukhbayar, Mirian Angulo Salazar, Alison Kennedy, Simon Newman, Benjamin Kendrick, Adrian Taylor, Rasheed Afinowi-Luitz, Roger Gundle, Bridget Watkins, Kim Wheway, Debra Beazley, Andrew Carr, Paresh Vyas

Blood (2022) 140 (Supplement 1): 2227–2228.

https://doi.org/10.1182/blood-2022-166474

Published: 2022

Journal Articles

Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia

Connor Sweeney, Gerda Mickute, Kinam Gupta, Marlen Metzner, Batchimeg Usukhbayar, Maria Chiara Barbanti, Gavinda Sangha, Ronjon Chakraverty, Persephone Borrow, Nicola Ternette, Ane Ogbe, Maria Aggelakopoulou, Paresh Vyas

Blood (2022) 140 (Supplement 1): 1576–1578.

https://doi.org/10.1182/blood-2022-166918

Published: 2022

Journal Articles

Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point

Naser Ansari-Pour, Verena Körber, Niels Asger Jakobsen, Rachel Moore, Nina Claudino, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Simon Newman, Benjamin Kendrick, Adrian Taylor, Rasheed Afinowi-Luitz, Roger Gundle, Bridget Watkins, Kim Wheway, Debra Beazley, Andrew Carr, Paresh Vyas, Thomas Höfer

Blood (2022) 140 (Supplement 1): 5753–5754.

https://doi.org/10.1182/blood-2022-166236

Published: 2022

Journal Articles

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis, Blanca Boluda, Jonathan Canaani, Pascal Turlure, Ann De Becker, Anand Tandra, Dina Elsouda, Arnaud Houweling, Anil Upadhyay, Isabelle Wouters, Paresh Vyas

Blood (2022) 140 (Supplement 1): 11641–11643.

https://doi.org/10.1182/blood-2022-156296

Published: 2022

Journal Articles

Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia

Douglas RA RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Sarah Mackie, Roan Hulks, Olena Yavorska, Paulina Siejka-Zielinska, Marlen Metzner, Alastair Smith, Batchimeg Usukhbayar, Virginie Penard-Lacronique, Chunxiao Song, Anita K. Gandhi, Maroof Hasan, Paresh Vyas, Thomas A. Milne, Skirmantas Kriaucionis, Lynn Quek

Blood (2022) 140 (Supplement 1): 8698–8699.

https://doi.org/10.1182/blood-2022-165898

Published: 2022

Journal Articles

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Blood (2022) 140 (Supplement 1): 532–533.

https://doi.org/10.1182/blood-2022-162245

Published: 2022

Journal Articles

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan

Blood (2022) 140 (Supplement 1): 732–734.

https://doi.org/10.1182/blood-2022-158967

Published: 2022

Journal Articles

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta

Blood (2022) 140 (16): 1816–1821.

https://doi.org/10.1182/blood.2022015909

Published: 2022

Includes: Supplemental data

NARROW

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Changing treatment changing prognosis of mutations

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A -Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

GATA1 Target Gene CSF2RB Is Functionally Coupled to MPL and Marks a TPO-Dependent Preleukemic TAM Cell Population Sustained By the Fetal Liver but Not Bone Marrow

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2 -Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia

Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation

Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia

Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only